Definium Therapeutics Announces New Employee Inducement Grants
Definium Therapeutics granted inducement options to purchase 45,940 common shares to two newly hired non-executive employees, with grant dates of October 13, 2026. The grants carry an exercise price equal to the grant-date closing price and vest over four years, approved under NASDAQ Rule 5635(c)(4) via the company's 2026 Inducement Plan.
Key figures
- Vesting
- 4 years; 25% at first anniversary, remainder monthly over 3 years
- Inducement options shares
- 45940
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.